Generic Name and Formulations:
Acetohydroxamic acid 250mg; tabs.
Mission Pharmacal Company
Indications for LITHOSTAT:
As adjunctive therapy in chronic urea-splitting urinary infection.
Initially 12mg/kg per day every 6–8hrs; max 1.5g/day. Renal impairment: serum creatinine >1.8mg/dL: take at every 12-hour intervals; max 1g/day.
Initially 10mg/kg per day; monitor. Titrate doses to obtain therapeutic effects.
Disease and physical state amenable to surgery and antimicrobials. Urine infected by non-urease producing organisms. Infections controllable by oral antimicrobials. Renal dysfunction (CrCl <20mL/min, serum creatinine >2.5mg/dL). Females with unsatisfactory method of contraception. Pregnancy (Cat.X).
Severe renal impairment: monitor and consider reduced dose. Monitor liver function. Preexisting thrombophlebitis or phlebothrombosis. Monitor and obtain CBCs with reticulocytes after 2 weeks of therapy and every 3 months thereafter; if reticulocytes >6%, consider reduced dose. Nursing mothers: not recommended.
Rash with concomitant alcohol. Concomitant dietary iron: may reduce absorption of both acetohydroxamic acid and iron (use IM inj form, if needed).
Mild headaches, tremulousness, nervousness, depression, anxiety, GI upset, hemolytic anemia, mild reticulocytosis without anemia, rash, alopecia, phlebitis, palpitations.
Endocrinology Advisor Articles
- Testosterone Use Remains High Among Men With Coronary Artery Disease
- Primary Characteristics of PCOS Predictive of Obstetric Complications
- Comparing Osteoporosis Screening, Treatment Strategies in Postmenopausal Women
- Maternal Thyroid Function in Pregnancy Linked to Childhood Risk for Disease
- Cerebral Small Vessel Disease More Common in Individuals With T1D vs General Population
- ADA's 2019 Standards of Medical Care in Diabetes Focus on Patient-Centered Care
- Sleep Habits Affect Insulin Sensitivity in Adolescents With Overweight, Obesity
- Levothyroxine Associated With Increased Mortality in Patients With Heart Failure
- Head-to-Head Comparison of Professional vs Personal CGM Systems in T1D
- Dual vs Triple Therapy for Metformin Treatment Intensification in Type 2 Diabetes
- Insulin Analogs vs Regular Human Insulin for Type 2 Diabetes
- Diabetic Ketoacidosis May Affect Brain Development in Children With T1D
- Higher Rates of Comorbidities Among Holocaust Survivors
- Population Health Data May Help Identify Patients at Risk for CVD
- Newborn Genomic Sequencing Can Identify Disease Risk